Puma Biotechnology (United States)
- Research works
- 80 ▲ 393% vs 2013–17
- Citations
- 1.3k 16.5 per fractional work
- Top-10% rate
- 13.8% record average 16.5%
- Open access
- 38% world 28%
Not ranked overall: Puma Biotechnology (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Nursing, 6.4×. Every wedge is a field page.
- Nursing 6.4×
- Biochemistry, Genetics and Molecular Biology 4.1×
- Medicine 3.1×
- Immunology and Microbiology 2.5×
- Pharmacology, Toxicology and Pharmaceutics 1.3×
- Decision Sciences 1.1×
- Chemistry 0.8×
- Engineering 0.4×
- Physics and Astronomy 0.3×
- Economics, Econometrics and Finance 0.3×
- Materials Science 0.3×
- Neuroscience 0.2×
- Mathematics 0.1×
- Computer Science 0.1×
Who are the top researchers at Puma Biotechnology (United States)?
Ranked on the composite score, Alshad S. Lalani and Richard Bryce lead among researchers whose main affiliation is Puma Biotechnology (United States).
- 1 Alshad S. Lalani United States · #439,722 worldwide 76 citations · 17 works
- 2 Richard Bryce United States · #704,484 worldwide 36 citations · 21 works
Which keywords describe research at Puma Biotechnology (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Breast Cancer, Chemotherapy, Metastatic Breast Cancer, Metastatic, Monoclonal Antibody, Trastuzumab, EGFR and HER2.
- Treatment Response
- Breast Tumours
- Neoadjuvant Therapy
- Signaling
- Gene Expression
- Rituximab
- Chemotherapy-Induced Peripheral Neuropathy
- Immunotherapy
- Therapeutic Antibodies
- Fc Receptors
- Survival Analysis
- Cancer
- EGFR Mutations
- Genomic Profiling
- Targeted Therapy
- CDK4/6 Inhibitors
- HER2
- Trastuzumab
- Metastatic
- Chemotherapy
- Breast Cancer
- Metastatic Breast Cancer
- Monoclonal Antibody
- EGFR
- Cell Cycle Control
- Palbociclib
- Clinical Trials
- ALK Inhibitors
- Prognostic Factors
- Glycosylation
- Clinical Practice Guidelines
- Quality of Life
- Cancer Therapy
- Molecular Subtypes
- Taxanes
- Chronic Lymphocytic Leukemia
- Genomic Aberrations
- Genomic Instability
- Population Dynamics
- Cancer Genomics
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Breast Cancer20▲ 90×5 topics
- Chemotherapy14▲ 25×10 topics
- Metastatic Breast Cancer12▲ 220×2 topics
- Metastatic10▲ 205×2 topics
- Monoclonal Antibody10▲ 186×2 topics
- Trastuzumab10▲ 300×2 topics
- EGFR10▲ 423×1 topic
- HER210▲ 423×1 topic
- Cell Cycle Control9▲ 461×2 topics
- CDK4/6 Inhibitors9▲ 712×1 topic
- Palbociclib9▲ 712×1 topic
- Targeted Therapy6▲ 34×4 topics
- Clinical Trials5▲ 9.7×5 topics
- Genomic Profiling4▲ 48×2 topics
- ALK Inhibitors4▲ 82×1 topic
- EGFR Mutations4▲ 82×1 topic
- Prognostic Factors4▲ 10.0×8 topics
- Cancer3▲ 3.0×14 topics
- Glycosylation3▲ 19×3 topics
- Survival Analysis3▲ 15×5 topics
- Clinical Practice Guidelines3▲ 7.0×6 topics
- Fc Receptors3▲ 36×1 topic
- Quality of Life3▲ 2.7×4 topics
- Therapeutic Antibodies3▲ 28×1 topic
- Cancer Therapy3▲ 5.2×9 topics
- Immunotherapy3▲ 5.1×10 topics
- Molecular Subtypes3▲ 39×2 topics
- Chemotherapy-Induced Peripheral Neuropathy3▲ 65×1 topic
- Taxanes3▲ 65×1 topic
- Rituximab2▲ 18×2 topics
- Chronic Lymphocytic Leukemia2▲ 52×1 topic
- Gene Expression2▲ 4.2×5 topics
- Genomic Aberrations2▲ 52×1 topic
- Signaling2▲ 20×2 topics
- Genomic Instability2▲ 18×2 topics
- Neoadjuvant Therapy2▲ 10×2 topics
- Population Dynamics2▲ 6.9×3 topics
- Breast Tumours2▲ 38×1 topic
- Cancer Genomics2▲ 34×1 topic
- Treatment Response2▲ 38×1 topic
Which research topics does Puma Biotechnology (United States) publish most on?
By volume in 2022–2025: HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Monoclonal and Polyclonal Antibodies Research and Breast Cancer Treatment Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 HER2/EGFR in Cancer Research Oncology 2 works
- 2 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
- 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 4 Breast Cancer Treatment Studies Cancer Research 1 works
- 5 Cancer Treatment and Pharmacology Oncology 0 works
- 6 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
- 7 Infant Nutrition and Health Nutrition and Dietetics 0 works
- 8 Glycosylation and Glycoproteins Research Molecular Biology 0 works
- 9 Lower Extremity Biomechanics and Pathologies Biomedical Engineering 0 works
- 10 Chronic Lymphocytic Leukemia Research Genetics 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Puma Biotechnology (United States)'s research output changed?
Output in 2018–2022 was 393% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Los Angeles
- University of California, Los Angeles
- University of Southern California
- Cedars-Sinai Medical Center
- Film Independent
- UCLA Health
- Children's Hospital of Los Angeles
- California State University Los Angeles
- Loyola Marymount University
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.